ADVANTAGENE, INC

Basic Information

440 Lexington St
AUBURNDALE, MA, 02466-1923

Company Profile

n/a

Additional Details

Field Value
DUNS: 192959851
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Clinically suitable approach for gene-mediated therapy of cirrhosis.

    Amount: $224,999.00

    Abstract Persistent injury to the liver can cause chronic inflammation and dysregulated deposition of extracellular matrix (ECM), leading to accumulation of fibrotic scar tissue and eventually cirrhos ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer

    Amount: $7,226,590.00

    DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a ...

    SBIR Phase II 2009 Department of Health and Human Services
  3. Improved system for producing adenoviral vectors

    Amount: $213,871.00

    First generation non-replicative adenoviral vectors show promise as anti-cancer agents and as prophylactic vaccines. Current methods for manufacturing these vectors use either the 293 cell line or t ...

    SBIR Phase I 2007 Department of Health and Human Services
  4. Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer

    Amount: $101,130.00

    DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a ...

    SBIR Phase I 2007 Department of Health and Human Services
  5. Clinical study of AdV-tk radiogenetherapy for malignant*

    Amount: $788,188.00

    DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic appr ...

    SBIR Phase II 2007 Department of Health and Human Services
  6. Clinical study of GMCI in Pancreatic Cancer

    Amount: $747,384.00

    DESCRIPTION (provided by applicant): Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the US; with less than one-year median survival, it accounts for approximately 30,000 dia ...

    SBIR Phase I 2006 Department of Health and Human Services
  7. Clinical study of AdV-tk radiogene therapy for glioma

    Amount: $758,386.00

    DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic appr ...

    SBIR Phase I 2004 Department of Health and Human Services
  8. Combination of GM-CSF with TKR gene therapy

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Combined gene therapy (Herpes Simplex Virus Thymidine Kinase + Anti-herpetic Prodrug) and radiation therapy (TKR therapy) is a novel approach in the armamentarium ...

    SBIR Phase I 2003 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government